期刊文献+

星点设计-效应面法优化普萘洛尔传递体的处方工艺 被引量:1

Study on the Optimal Formulation and Preparation Conditions of Propranolol-loaded Transfersomes by Central Composite Design and Response Surface Method
原文传递
导出
摘要 目的应用星点设计-效应面法优化普萘洛尔传递体的处方工艺。方法采用硫酸铵梯度法制备普萘洛尔传递体。将药物/磷脂摩尔比、Span-80/磷脂摩尔比、探头超声时间作为考察因素,以包封率、载药量、平均粒径及变形性指数为效应指标,求算总评"归一值"并采用Design-Expert 8.0软件进行效应面法优化,确定最佳处方工艺并进行验证。结果确定最优制备工艺为:药物/磷脂摩尔比19.83%、Span-80/磷脂摩尔比21.08%、探头超声时间10.29 min,以该处方工艺制备所得传递体的包封率、载药量、平均粒径及变形性指数分别为76.63%,4.80%,52.82 nm,20.83,且实测值与预测值的偏差均较小。结论星点设计-效应面法适用于普萘洛尔传递体的处方工艺优化,优化所得处方工艺稳定、可行。 OBJECTIVE To optimize the formulation and preparation of propranolol-loaded transfersomes by central composite design and response surface method. METHODS Transfersomes were prepared using the ammonium sulfate gradient method. The effects of drug/lipoid molar ratio, Span-80 molar ratio and time of probe ultrasonication on entrapment efficiency, drug-loading, vesicle size and deformability index were investigated. After each overall desirability was calculated, the optimal conditions for preparing propranolol transfersomes were achieved by Design-Expert 8.0 software, and were validated experimentally. RESULTS The optimal preparation conditions were determined as drug molar ratio 19.83%, Span-80/lipoid molar ratio 21.08%, time of probe ultrasonication 10.29 min. Under these conditions, the evaluated entrapment efficiency, drug-loading, vesicle size and deformability index of propranolol transfersomes were 76.63%, 4.80%, 152.82 nm, 20.83 respectively, and all approximated to the forecasted ones. CONCLUSION The central composite design and response surface method is applicable for the formulation and preparation conditions of optimization of propranolol transfersomes, and the resulting optimal preparation technique is stable and feasible.
出处 《中国现代应用药学》 CAS CSCD 2012年第12期1107-1112,共6页 Chinese Journal of Modern Applied Pharmacy
基金 南京医科大学科技发展基金重点项目(2010NJMUZ10)
关键词 普萘洛尔 传递体 SPAN-80 星点设计 效应面 propranolol transfersomes Span-80 central composite design response surface
  • 相关文献

参考文献15

  • 1LEAUTE-LABREZE C, DUMAS DE LA ROQUE E, HUBICHE T, et al. Propranolol for severe hemangiomas of infancy [J]. N Eng J Med, 2008, 358(24): 2649-2651.
  • 2DENOYELLE F, LEBOULANGER N, ENJOLRAS O, et al. Role of propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma [J]. Int J Pediatr Otorhino- laryngol, 2009, 73(8): 1168-1172.
  • 3DENOYELLE F, GARABEDIAN E N. Propranolol may become first-line treatment in obstructive subglottic infantile bemangiomas [J]. Otolaryngol Head Neck Surg, 2010, 142(3): 463-464.
  • 4HOLMES W J, MISHRA A, GORST C, et al. Propranolol as first-line treatment for infantile hemangiomas [J]. Plast Reconstr Surg, 2010, 125(1): 420-421.
  • 5SIEGFRIED E C, KEENAN W J, AL-JUREID1NI S. More on propranolol for hemangiomas of infancy [J]. N Eng J Med, 2008, 359(26): 2846-2847.
  • 6HOLLAND K E, FRIEDEN I J, FROMMELT P C, et al. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma [J]. Arch Dermatol, 2010, 146(7): 775-778.
  • 7YANG B F, SU D F, ZHOU H H. Pharmacology(药理学) [M] 7th ed. Beijing: People's Medical Publishing House, 2008: 103.
  • 8CEVC G, MAZGAREANU S, ROTHER M. Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels [J]. Int J Pharm, 2008, 360(1/2): 29-39.
  • 9KNEER W, ROTHER I, ROTHER M, et al. A multiple-dose, open-label, safety, compliance, and usage evaluation study of epicutaneously applied Diractin (ketoprofen in Transfersome) in joint/musculoskeletal pain or soft tissue inflammation [J]. Curr Drug Saf, 2009, 4(1): 5-10.
  • 10ROTHER M, SEIDEL E J, CLARKSON P M, et al. Efficacy of epicutaneous Diractin (ketoprofen in Transfersome gel) for the treatment of pain related to eccentric muscle contractions [J]. Drug Des Devel Ther, 2009(3): 143-149.

二级参考文献17

共引文献523

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部